230 related articles for article (PubMed ID: 6145425)
1. Pharmacology of fluperlapine compared with clozapine.
Eichenberger E
Arzneimittelforschung; 1984; 34(1A):110-3. PubMed ID: 6145425
[TBL] [Abstract][Full Text] [Related]
2. CI-943, a potential antipsychotic agent. II. Neurochemical effects.
Pugsley TA; Coughenour LL; Myers SL; Shih YH; Courtland GG; Berghoff W; Stewart SF
J Pharmacol Exp Ther; 1989 Oct; 251(1):113-22. PubMed ID: 2571713
[TBL] [Abstract][Full Text] [Related]
3. The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and in the prefrontal cortex of freely moving rats.
Imperato A; Angelucci L
Psychopharmacol Bull; 1989; 25(3):383-9. PubMed ID: 2576318
[TBL] [Abstract][Full Text] [Related]
4. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841.
Krisch I; Bole-Vunduk B; Pepelnak M; Lavric B; Ocvirk A; Budihna MV; Sket D
J Pharmacol Exp Ther; 1994 Oct; 271(1):343-52. PubMed ID: 7965734
[TBL] [Abstract][Full Text] [Related]
6. In vivo actions of clozapine and haloperidol on the turnover rate of acetylcholine in rat striatum.
Racagni G; Cheney DL; Trabucchi M; Costa E
J Pharmacol Exp Ther; 1976 Feb; 196(2):323-32. PubMed ID: 943521
[TBL] [Abstract][Full Text] [Related]
7. Effects of fluperlapine on dopaminergic systems in rat brain.
Burki HR
Psychopharmacology (Berl); 1986; 89(1):77-84. PubMed ID: 2942961
[TBL] [Abstract][Full Text] [Related]
8. Pharmaco-EEG studies with fluperlapine.
Matejcek M; Neff G; Tjeerdsma H; Krebs E
Arzneimittelforschung; 1984; 34(1A):114-20. PubMed ID: 6145426
[TBL] [Abstract][Full Text] [Related]
9. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies.
Nemeroff CB; Luttinger D; Hernandez DE; Mailman RB; Mason GA; Davis SD; Widerlöv E; Frye GD; Kilts CA; Beaumont K; Breese GR; Prange AJ
J Pharmacol Exp Ther; 1983 May; 225(2):337-45. PubMed ID: 6682440
[TBL] [Abstract][Full Text] [Related]
10. [Effects of anticholinergics and clozapine on the activation of the striatal dopaminergic system in the rat by haloperidol. Pharmacological findings (author's transl)].
Sayers AC; Bürki HR
Arzneimittelforschung; 1976; 26(6):1092-3. PubMed ID: 989384
[TBL] [Abstract][Full Text] [Related]
11. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T
J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
[TBL] [Abstract][Full Text] [Related]
13. Behavioral and biochemical aspects of neuroleptic-induced dopaminergic supersensitivity: studies with chronic clozapine and haloperidol.
Seeger TF; Thal L; Gardner EL
Psychopharmacology (Berl); 1982; 76(2):182-7. PubMed ID: 6805029
[TBL] [Abstract][Full Text] [Related]
14. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat.
Rupniak NM; Hall MD; Mann S; Fleminger S; Kilpatrick G; Jenner P; Marsden CD
Biochem Pharmacol; 1985 Aug; 34(15):2755-63. PubMed ID: 4040370
[TBL] [Abstract][Full Text] [Related]
15. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats.
Rupniak NM; Kilpatrick G; Hall MD; Jenner P; Marsden CD
Psychopharmacology (Berl); 1984; 84(4):512-9. PubMed ID: 6441952
[TBL] [Abstract][Full Text] [Related]
16. Neuropsychopharmacological profile of remoxipride in comparison with clozapine.
Skuza G; Rogóz Z; Wieczorek A
Pol J Pharmacol; 1997; 49(1):5-15. PubMed ID: 9431546
[TBL] [Abstract][Full Text] [Related]
17. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain.
Reches A; Burke RE; Kuhn CM; Hassan MN; Jackson VR; Fahn S
J Pharmacol Exp Ther; 1983 Jun; 225(3):515-21. PubMed ID: 6864517
[TBL] [Abstract][Full Text] [Related]
18. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
[TBL] [Abstract][Full Text] [Related]
19. Differential alteration of striatal D-1 and D-2 receptors induced by the long-term administration of haloperidol, sulpiride or clozapine to rats.
Jenner P; Rupniak NM; Marsden CD
Psychopharmacology Suppl; 1985; 2():174-81. PubMed ID: 3159009
[TBL] [Abstract][Full Text] [Related]
20. Possible significance of clozapine-induced increase in brain dopamine.
Gianutsos G; Moore KE
Res Commun Chem Pathol Pharmacol; 1977 May; 17(1):29-39. PubMed ID: 877404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
